Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

Next Previous
X
Search
Trial Profile

The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Cyclophosphamide (Primary) ; Decitabine (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary) ; Prednisone (Primary) ; Tucidinostat (Primary) ; Vincristine (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 10 Jun 2023 Planned End Date changed from 20 Jun 2024 to 1 Apr 2024.
    • 10 Jun 2023 Status changed from recruiting to active, no longer recruiting.
    • 08 Nov 2022 Planned primary completion date changed from 20 Jun 2022 to 20 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top